• The Company
    • Company Overview

    • Technology Overview

    • Leadership
      • Robert Freedman, CEO

      • Cheul H. Cho, CSO

      • Christian T. Darabant, COO

      • Leslie Z. Benet

      • James S. MacDonald

      • Martin L. Yarmush

    • Investor Relations

  • Products & Services
    • HµREL® microlivers

    • Products

    • Contract Services

    • HµRELToxTM

    • HµRELviralTM

    • HµRELfluxTM

    • HµRELZooPlateTM

    • ACEA/HµREL®
      continuous monitoring

  • Publications
    • Scientific papers

    • Videos

    • Webinars

    • Industry collaborations

  • News & Events
    • News & Press Releases

    • Coming Events

    • Webinars

  • Customer Service

HµRELToxTM
multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
HµRELviralTM
Long-enduring infectious liver disease platform
Time-Based
Toxicity Ratios*
A new marker for hepatotoxic chronicity

TAAP
*patent pending
HµRELfluxTM
a new, patent-pending
efflux transport
assay method
DMPK
Superior intrinsic clearance
and biotransformation of
low-turnover drugs

DMD

News
Coming Events
  • May 2019
    Hurel announces partnership with Cyprotex. Read the announcement here. View the data sheet here.
  • November 2018
    Q2 Solutions paper on Hurel is featured in Drug Metabolism and Disposition special issue devoted to New Models in Drug Metabolism and Transport. (download publication)
Entire News Chronology
  • 2020 NJDMDG Spring Symposium and Vendor Exhibition

    Date: September 10, 2020 (tentative)

    Location: TBD

    Topic: TBD

Entire List of Coming Events
divide
bottomtag
linkedin  facebook  twitter
divide
The Company  Technology  Products & Services  Publications  News & Events  Contact  Site Map
Copyright © 2013 Hµrel® Corporation